All Stories

  1. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma

    Article • Oncotarget, October 2016, Impact Journals, LLC

    Dr Yun Dai

  2. Abstract 3020: Targeting both canonical and non-canonical NF-kB pathways by the IAP antagonist birinapant potentiates bortezomib anti-myeloma activity

    Article • Cancer Research, July 2016, American Association for Cancer Research (AACR)

    Dr Yun Dai

  3. Nonlinear response surface in the study of interaction analysis of three combination drugs

    Article • Biometrical Journal, May 2016, Wiley

    Dr Yun Dai

  4. Abstract B15: Targeting SQSTM1/p62 induces cargo-loading failure and converts autophagy to apoptosis via NBK/Bik in human multiple myeloma cells.

    Article • Clinical Cancer Research, August 2015, American Association for Cancer Research (AACR)

    Dr Yun Dai

  5. Abstract LB-258: The NAE inhibitor pevonedistat (MLN4924) interacts with the HDAC inhibitor belinostat via disruption of the intra-S checkpoint and both HR and NHEJ DNA repair in AML cells

    Article • Cancer Research, August 2015, American Association for Cancer Research (AACR)

    Dr Yun Dai

  6. BCL2L11/Bim as a dual-agent regulating autophagy and apoptosis in drug resistance

    Article • Autophagy, February 2015, Taylor & Francis

    Dr Yun Dai

  7. Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: A novel synergistic therapeutic approach

    Article • Experimental Hematology, February 2015, Elsevier

    Dr Yun Dai

  8. 107

    Article • Cytokine, November 2014, Elsevier

    Dr Yun Dai

  9. Abstract 4600: P-TEFb is a therapeutic target in human bortezomib-resistant multiple myeloma cells

    Article • Cancer Research, September 2014, American Association for Cancer Research (AACR)

    Dr Yun Dai

  10. Abstract 1772: Overcoming drug-resistance in multiple myeloma by CRM1 inhibitor combination therapy

    Article • Cancer Research, September 2014, American Association for Cancer Research (AACR)

    Dr Yun Dai

  11. Abstract 4556: A therapeutic strategy combining the Wee1 inhibitor MK1775 with HDAC inhibitors targets both p53 wild-type or mutant AML cells

    Article • Cancer Research, September 2014, American Association for Cancer Research (AACR)

    Dr Yun Dai

  12. A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis

    Article • Blood, September 2014, American Society of Hematology

    Dr Yun Dai

  13. Inhibition of the MDM2 E3 Ligase Induces Apoptosis and Autophagy in Wild-Type and Mutant p53 Models of Multiple Myeloma, and Acts Synergistically with ABT-737

    Article • PLoS ONE, September 2014, PLOS

    Dr Yun Dai

  14. Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights

    Article • Pharmacology & Therapeutics, September 2014, Elsevier

    Dr Yun Dai

  15. Targeting SQSTM1/p62 Induces Cargo Loading Failure and Converts Autophagy to Apoptosis via NBK/Bik

    Article • Molecular and Cellular Biology, July 2014, ASM Journals

    Dr Yun Dai

  16. Circumvention of Mcl-1-Dependent Drug Resistance by Simultaneous Chk1 and MEK1/2 Inhibition in Human Multiple Myeloma Cells

    Article • PLoS ONE, March 2014, PLOS

    Dr Yun Dai

  17. PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells

    Article • Cancer Biology & Therapy, May 2013, Taylor & Francis

    Dr Yun Dai

  18. Abstract 3390: Simultaneous Chk1 and MEK1/2 inhibition circumvents Mcl-1-mediated anti-apoptotic functions and bortezomib resistance in human multiple myeloma cells.

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    Dr Yun Dai

  19. Abstract 3420: The novel Chk1 inhibitor MK8776 sensitizes AML cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair.

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    Dr Yun Dai

  20. Abstract 3346: A20/TNFAIP3, a novel target of histone deacetylase inhibitor-induced NF-κB activation, functionally disables the extrinsic apoptotic pathway in human leukemia cells.

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    Dr Yun Dai

  21. The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair

    Article • Molecular Cancer Therapeutics, March 2013, American Association for Cancer Research (AACR)

    Dr Yun Dai

  22. A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax®)

    Article • Epigenomics, October 2012, Future Medicine

    Dr Yun Dai

  23. Resveratrol Sensitizes Acute Myelogenous Leukemia Cells to Histone Deacetylase Inhibitors through Reactive Oxygen Species-Mediated Activation of the Extrinsic Apoptotic Pathway

    Article • Molecular Pharmacology, August 2012, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Yun Dai

  24. CDK Inhibitors Upregulate BH3-Only Proteins to Sensitize Human Myeloma Cells to BH3 Mimetic Therapies

    Article • Cancer Research, June 2012, American Association for Cancer Research (AACR)

    Dr Yun Dai

  25. Poly(ADP-ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Mammary Tumors

    Article • Molecular Pharmacology, May 2012, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Yun Dai

  26. Abstract 4706: Resveratrol potentiates the lethality of HDAC inhibitors in acute myelogenous leukemia cells

    Article • Cancer Research, April 2012, American Association for Cancer Research (AACR)

    Dr Yun Dai

  27. Abstract 4667: Simultaneous Chk1 and MEK1/2 inhibition circumvents Mcl-1 anti-apoptotic function and bortezomib resistance in human multiple myeloma cells

    Article • Cancer Research, April 2012, American Association for Cancer Research (AACR)

    Dr Yun Dai

  28. Abstract 4649: Nbk/Bik induced by flavopiridol switches GX15-070-induced autophagy to apoptosis in human multiple myeloma cells

    Article • Cancer Research, April 2012, American Association for Cancer Research (AACR)

    Dr Yun Dai

  29. Enhancing CHK1 inhibitor lethality in glioblastoma

    Article • Cancer Biology & Therapy, April 2012, Taylor & Francis

    Dr Yun Dai

  30. LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism

    Article • Leukemia Research, April 2012, Elsevier

    Dr Yun Dai

  31. Histone Deacetylase Inhibitors and Rational Combination Therapies

    Article • January 2012, Elsevier

    Dr Yun Dai

  32. Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2

    Article • Blood, September 2011, American Society of Hematology

    Dr Yun Dai

  33. The Role of Tyk2 in Regulation of Breast Cancer Growth

    Article • Journal of Interferon & Cytokine Research, September 2011, Mary Ann Liebert Inc

    Dr Yun Dai

  34. Disruption of I B Kinase (IKK)-mediated RelA Serine 536 Phosphorylation Sensitizes Human Multiple Myeloma Cells to Histone Deacetylase (HDAC) Inhibitors

    Article • Journal of Biological Chemistry, August 2011, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Yun Dai

  35. Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death

    Article • Cancer Biology & Therapy, August 2011, Taylor & Francis

    Dr Yun Dai

  36. Abstract 5367: Simultaneous inhibition of Chk1 and MEK1/2 targets non-proliferating multiple myeloma cells

    Article • Cancer Research, April 2011, American Association for Cancer Research (AACR)

    Dr Yun Dai

  37. Abstract 2572: The histone deacetylase inhibitors (HDACIs) vorinostat and entinostat interact synergistically with the Bcr/Abl, FLT3, and aurora kinase inhibitor KW-2449 to induce apoptosis in imatininb mesylate (IM)-sensitive and -resistant CML and A...

    Article • Cancer Research, April 2011, American Association for Cancer Research (AACR)

    Dr Yun Dai

  38. HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo

    Article • Clinical Cancer Research, April 2011, American Association for Cancer Research (AACR)

    Dr Yun Dai

  39. CHK1 Inhibitors in Combination Chemotherapy: Thinking Beyond the Cell Cycle

    Article • Molecular Interventions, April 2011, CLOCKSS Archive

    Dr Yun Dai

  40. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF‐κB and Bim

    Article • British Journal of Haematology, March 2011, Wiley

    Dr Yun Dai

  41. Rational Combination of Targeted Agents to Overcome Cancer Cell Resistance

    Article • January 2011, Springer Science + Business Media

    Dr Yun Dai

  42. Methods to Study Cancer Therapeutic Drugs That Target Cell Cycle Checkpoints

    Article • January 2011, Springer Science + Business Media

    Dr Yun Dai

  43. Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo

    Article • Blood, December 2010, American Society of Hematology

    Dr Yun Dai

  44. The NF (Nuclear factor)‐κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1‐dependent apoptosis in human acute myeloid leukaemia cells

    Article • British Journal of Haematology, August 2010, Wiley

    Dr Yun Dai

  45. Abstract 5412: Synergistic interactions between histone deacetylase inhibitors and aurora kinase inhibitor KW2449 Ph+ cells

    Article • Cancer Research, April 2010, American Association for Cancer Research (AACR)

    Dr Yun Dai

  46. Abstract 667: Mechanisms underlying synergistic interactions between the CDK inhibitor flavopiridol (Alvocidib) and the BH3 mimetic GX15-070 (Obatoclax) in human multiple myeloma cells

    Article • Cancer Research, April 2010, American Association for Cancer Research (AACR)

    Dr Yun Dai

  47. Targeting Chk1 in the replicative stress response

    Article • Cell Cycle, March 2010, Taylor & Francis

    Dr Yun Dai

  48. New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network

    Article • Clinical Cancer Research, January 2010, American Association for Cancer Research (AACR)

    Dr Yun Dai

  49. Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-xL, and Mcl-1

    Article • Molecular and Cellular Biology, October 2009, ASM Journals

    Dr Yun Dai

  50. Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells

    Article • Blood, July 2008, American Society of Hematology

    Dr Yun Dai

  51. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate

    Article • Blood, May 2008, American Society of Hematology

    Dr Yun Dai

  52. Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo

    Article • Molecular Cancer Therapeutics, March 2008, American Association for Cancer Research (AACR)

    Dr Yun Dai

  53. Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells

    Article • Clinical Cancer Research, January 2008, American Association for Cancer Research (AACR)

    Dr Yun Dai

  54. CDK Inhibitors in Multiple Myeloma

    Article • January 2008, Springer Science + Business Media

    Dr Yun Dai

  55. Synergistic Interactions between Vorinostat and Sorafenib in Chronic Myelogenous Leukemia Cells Involve Mcl-1 and p21CIP1 Down-Regulation

    Article • Clinical Cancer Research, July 2007, American Association for Cancer Research (AACR)

    Dr Yun Dai

  56. MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism

    Article • Blood, May 2007, American Society of Hematology

    Dr Yun Dai

  57. Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation

    Article • Blood, May 2007, American Society of Hematology

    Dr Yun Dai

  58. Targeting Multiple Arms of the Apoptotic Regulatory Machinery

    Article • Cancer Research, April 2007, American Association for Cancer Research (AACR)

    Dr Yun Dai

  59. Mcl-1 Down-regulation Potentiates ABT-737 Lethality by Cooperatively Inducing Bak Activation and Bax Translocation

    Article • Cancer Research, January 2007, American Association for Cancer Research (AACR)

    Dr Yun Dai

  60. Dissecting the Roles of Checkpoint Kinase 1/CDC2 and Mitogen-Activated Protein Kinase Kinase 1/2/Extracellular Signal-Regulated Kinase 1/2 in Relation to 7-Hydroxystaurosporine-Induced Apoptosis in Human Multiple Myeloma Cells

    Article • Molecular Pharmacology, August 2006, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Yun Dai

  61. Cyclin D1 Overexpression Increases the Susceptibility of Human U266 Myeloma Cells to CDK Inhibitors through a Process Involving p130-, p107- and E2F-Dependent S-Phase Entry

    Article • Cell Cycle, February 2006, Taylor & Francis

    Dr Yun Dai

  62. CDK inhibitor targets—A hit or miss proposition?: Cyclin-dependent kinase inhibitors kill tumor cells by downregulation of antiapoptotic proteins

    Article • Cancer Biology & Therapy, February 2006, Taylor & Francis

    Dr Yun Dai

  63. Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor re-growth

    Article • Cancer Biology & Therapy, November 2005, Taylor & Francis

    Dr Yun Dai

  64. Blockade of Histone Deacetylase Inhibitor-Induced RelA/p65 Acetylation and NF-κB Activation Potentiates Apoptosis in Leukemia Cells through a Process Mediated by Oxidative Damage, XIAP Downregulation, and c-Jun N-Terminal Kinase 1 Activation

    Article • Molecular and Cellular Biology, July 2005, ASM Journals

    Dr Yun Dai

  65. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation

    Article • Leukemia, September 2004, Springer Science + Business Media

    Dr Yun Dai

  66. A Bcr/Abl-independent, Lyn-dependent Form of Imatinib Mesylate (STI-571) Resistance Is Associated with Altered Expression of Bcl-2

    Article • Journal of Biological Chemistry, June 2004, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Yun Dai

  67. Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents

    Article • Current Oncology Reports, April 2004, Springer Science + Business Media

    Dr Yun Dai

  68. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-κB-dependent process

    Article • Oncogene, October 2003, Springer Science + Business Media

    Dr Yun Dai

  69. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells

    Article • Leukemia, September 2003, Springer Science + Business Media

    Dr Yun Dai

  70. An Intact NF-kappaB Pathway is Required for Histone Deacetylase Inhibitor Induced G1 Arrest and Maturation in U937 Human Myeloid Leukemia Cells

    Article • Cell Cycle, September 2003, Taylor & Francis

    Dr Yun Dai

  71. Enforced expression of the tumor suppressor p53 renders human leukemia cells (U937) more sensitive to 1-[β-d-arabinofuranosyl]cytosine (ara-C)-induced apoptosis

    Article • Biochemical Pharmacology, June 2003, Elsevier

    Dr Yun Dai

  72. Coadministration of UCN-01 with MEK1/2 Inhibitors Potently Induces Apoptosis in

    Article • Cancer Biology & Therapy, November 2002, Taylor & Francis

    Dr Yun Dai

  73. Inhibitors of MEK1/2 Interact with UCN-01 to Induce Apoptosis and Reduce Colony Formation in Mammary and Prostate Carcinoma Cells

    Article • Cancer Biology & Therapy, May 2002, Taylor & Francis

    Dr Yun Dai

  74. Loss of the BCL-2 Phosphorylation Loop Domain Is Required to Protect Human Myeloid Leukemia Cells from Flavopiridol-Mediated Mitochondrial Damage and Apoptosis

    Article • Cancer Biology & Therapy, March 2002, Taylor & Francis

    Dr Yun Dai

  75. Induction of Apoptosis in Human Leukemia Cells by the CDK1 Inhibitor

    Article • Cell Cycle, March 2002, Taylor & Francis

    Dr Yun Dai

  76. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway

    Article • Cell Death and Differentiation, July 2001, Springer Science + Business Media

    Dr Yun Dai